Cas:637301-19-0 tert-butyl 8-oxo-3-azabicyclo[3.2.1]octane-3-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 8-oxo-3-azabicyclo[3.2.1]octane-3-carboxylate

CAS.NO:637301-19-0

Synonyms:tert-butyl 8-oxo-3-azabicyclo[3.2.1]octane-3-carboxylate;3-Boc-3-azabicyclo[3.2.1]octan-8-one

Molecular Formula:C₁₂H₁₉NO₃

Molecular Weight:225.28400

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.139±0.06 g/cm3

Index of Refraction:

PSA:46.61000

Exact Mass:225.13600

LogP:1.77030

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl 8-oxo-3-azabicyclo[3.2.1]octane-3-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Boc-3-azabicyclo[3.2.1]octan-8-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Boc-3-azabicyclo[3.2.1]octan-8-one Use and application,3-Boc-3-azabicyclo[3.2.1]octan-8-one technical grade,usp/ep/jp grade.

Related News: Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease. tert-butyl 8-oxo-3-azabicyclo[3.2.1]octane-3-carboxylate manufacturer High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies. tert-butyl 8-oxo-3-azabicyclo[3.2.1]octane-3-carboxylate supplier In that group, the vaccine slowed brain decline by around 30% in two different clinical and functional tests, Novak said. tert-butyl 8-oxo-3-azabicyclo[3.2.1]octane-3-carboxylate vendor On the basis of achieving low-cost and high-quality processes, production capacity will become the core driving force for API companies to break through sales bottlenecks. tert-butyl 8-oxo-3-azabicyclo[3.2.1]octane-3-carboxylate factory The drug, Imfinzi, when added to chemotherapy and the drugmaker��s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.